In consistent with these in vitro results, GPX4 and FSP1 levels were sufficiently reduced after CAP treatment, elevated in mice tumor samples carrying EGFR(Y1068F) mutation, and non-distinguishable in the 'EGFR(Y1068F)+CAP' group as compared with the control (mice inoculated with SUM159PT cells) (Figure 2L). This evidence concerns the gene AIFM2 and neoplasm.